Previous 10 | Next 10 |
2024-01-05 09:33:29 ET More on Avenue Therapeutics Avenue Therapeutics GAAP EPS of $0.06 beats by $0.32 Avenue Therapeutics stock plummets on pricing of 16.6M units at $0.3006 in public offering Seeking Alpha’s Quant Rating on Avenue Therapeutics Histo...
MIAMI, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced the...
2024-01-04 21:57:41 ET DENVER, Colo., Jan. 4, 2024 ( www.247marketnews.com )- 24/7 Market News covered the following companies today; Omega Therapeutics, Inc. (NASDAQ: OMGA), Avenue Therapeutics, Inc. (NASDAQ: ATXI), QuantumScape (NYSE: QS), Jeffs Brands Ltd (NASDAQ: JFBR), Dyne Therape...
2024-01-04 12:34:16 ET More on Mid-day movers & Stocks. Relmada Therapeutics, Inc. (RLMD) Q3 2023 Earnings Call Transcript Relmada And REL-1017: Intriguing Underlying Efficacy In MDD Ahead Of Eventful 2024 Avenue Therapeutics GAAP EPS of $0.06 beats by $0.32 ...
2024-01-04 12:31:41 ET DENVER, Colo., Jan. 4, 2024 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual midday volume; Omega Therapeutics Inc (NASDAQ: OMGA), Avenue Therapeutics Inc (NASDAQ: ATXI), Nikola Corp (NASDAQ: NKL...
2024-01-04 10:00:42 ET DENVER, Colo., Jan. 4, 2024 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; Omega Therapeutics Inc (NASDAQ: OMGA), Avenue Therapeutics Inc (NASDAQ: ATXI), Rapid Micro Biosystems Inc (NAS...
2024-01-04 08:58:40 ET DENVER, Colo., Jan. 4, 2024 ( www.247marketnews.com )- Avenue Therapeutics, Inc. (NASDAQ: ATXI) reported, this morning, that it reached final agreement with the U.S. Food and Drug Administration (“FDA”) on the Phase 3 safety study protocol and statis...
MIAMI, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced tha...
- Topline data remains on track for second quarter of 2024 - MIAMI, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of th...
MIAMI, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced tha...
News, Short Squeeze, Breakout and More Instantly...
Avenue Therapeutics Inc. Company Name:
ATXI Stock Symbol:
NASDAQ Market:
Avenue Therapeutics Inc. Website:
MIAMI, June 20, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced tha...
MIAMI, May 16, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced the ...
– Raised a total of $9.4 million in gross proceeds from warrant exercise transactions since January 2024 – MIAMI, May 15, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutica...